Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the United States.
The last earnings update was 90 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Bionomics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Bionomics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Bionomics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Bionomics's revenue is expected to grow by 14.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Bionomics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Before You Buy Bionomics Limited (ASX:BNO), Consider Its Volatility
Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … This is above 1, so historically its share price has been influenced by the broader volatility of the stock market.
Easy Come, Easy Go: How Bionomics (ASX:BNO) Shareholders Got Unlucky And Saw 88% Of Their Cash Evaporate
See our latest analysis for Bionomics Given that Bionomics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Over half a decade Bionomics reduced its trailing twelve month revenue by 5.3% for each year. … Of course Bionomics may not be the best stock to buy.
Is Bionomics Limited (ASX:BNO) A Financially Sound Company?
Investors are always looking for growth in small-cap stocks like Bionomics Limited (ASX:BNO), with a market cap of AU$74m. … However, an important fact which most ignore is: how financially healthy is the business? … the current state of its operations and pathway to profitability.
Did Changing Sentiment Drive Bionomics's (ASX:BNO) Share Price Down A Painful 72%?
Given that Bionomics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … Bionomics's revenue didn't grow at all in the last year.
Does Bionomics Limited (ASX:BNO) Have A Particularly Volatile Share Price?
Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.
Does Market Volatility Impact Bionomics Limited's (ASX:BNO) Share Price?
Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.
In this analysis, my focus will be on developing a perspective on Bionomics Limited’s (ASX:BNO) latest ownership structure, a less discussed, but important factor. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.
Analysts Expect Breakeven For Bionomics Limited (ASX:BNO)
The AU$260.70m market-cap company’s loss lessens since it announced a -AU$6.75m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -AU$5.90m, as it approaches breakeven? … I’ve put together a brief outline of industry analyst expectations for BNO, its year of breakeven and its implied growth rate … According to the industry analysts covering BNO, breakeven is near.
When Can We Expect A Profit From Bionomics Limited (ASX:BNO)?
In this article, I will touch on the expectations for BNO’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 92.12% year-on-year, on average, which signals high confidence from analysts. … Next Steps: There are too many aspects of BNO to cover in one brief article, but the key fundamentals for the company can all be found in one place – BNO’s company page on Simply Wall St.
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company’s lead product candidate includes BNC210, a negative allosteric modulator, which is in various clinical trials for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. In addition, the company offers contract research services. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.